Renal Cancer Clinical Trials in New York, New York

6 studies are recruiting for renal cancer in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

   This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other parts of the body). The study will look at the safety of the…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Icahn School of Medicine at Mount Sinai, New York, New York

   Locations

   162 in total

   Run by

   Pfizer

   See if you can join NCT07227415 on ClinicalTrials.gov

2. Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies

   Background: - Laboratory investigators who are studying common childhood cancers are interested in developing a tissue repository to collect and store blood, serum, tissue, urine, or tumors of children who have cancer or adults who have common childhood cancers. To develop this repository, addition…

   Stage

   Not phased

   Ages

   0 and older

   Site

   Tisch Cancer Institute, Mount Sinai Medical Center, New York, New York

   Locations

   5 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT01109394 on ClinicalTrials.gov

3. A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

   This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (Hippo Pathway altera…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   15 in total

   Run by

   Nuvectis Pharma, Inc.

   See if you can join NCT05873686 on ClinicalTrials.gov

4. Kidney Cancer DNA Registry

   This registry will help us develop better methods of: * Preventing these cancers * Diagnosing these cancers * Treating these cancers

   Stage

   Not phased

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT02087852 on ClinicalTrials.gov

5. Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders

   The purpose of this study is to better understand the genetic causes of Hodgkin's disease (a kind of lymphoma) and non-Hodgkin's lymphoma, as well as multiple myeloma, leukemia, and related diseases. The doctors have identified the patient because 1) they have had a lymphoproliferative disorder suc…

   Stage

   Not phased

   Ages

   Any age

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   6 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT00582621 on ClinicalTrials.gov

6. Decision Aid (DA) for Renal Patients

   The objective of this study is to understand how patients make decisions about treating their kidney masses, and to identify key values and preferences for treating their kidney masses. The study team will develop a decision aid (DA) using the decision-analytic model to communicate personalized ben…

   Stage

   Not phased

   Ages

   18 and older

   Site

   NYU Langone Health, New York, New York

   Run by

   NYU Langone Health

   See if you can join NCT05387863 on ClinicalTrials.gov